PuSH - Publikationsserver des Helmholtz Zentrums München

Knerr, P.J.* ; Mowery, S.A.* ; Finan, B.* ; Perez-Tilve, D.* ; Tschöp, M.H. ; DiMarchi, R.D.*

Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.

Peptides 125:170225 (2020)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The continued global growth in the prevalence of obesity coupled with the limited number of efficacious and safe treatment options elevates the importance of innovative pharmaceutical approaches. Combinatorial strategies that harness the metabolic benefits of multiple hormonal mechanisms have emerged at the preclinical and more recently clinical stages of drug development. A priority has been anti-obesity unimolecular peptides that function as balanced, high potency poly-agonists at two or all the cellular receptors for the endocrine hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This report reviews recent progress in this area, with emphasis on what the initial clinical results demonstrate and what remains to be addressed.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Obesity ; Type 2 Diabetes ; Poly-agonism ; Gip ; Glp-1 ; Glucagon; Dependent Insulinotropic Polypeptide; High-fat Diet; Peptide-1 Receptor; Body-weight; Bariatric Surgery; Corrects Obesity; Glycemic Control; Clinical-trials; Hybrid Peptide; Co-agonism
ISSN (print) / ISBN 0196-9781
e-ISSN 1873-5169
Zeitschrift Peptides
Quellenangaben Band: 125, Heft: , Seiten: , Artikelnummer: 170225 Supplement: ,
Verlag Elsevier
Verlagsort New York, NY
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed